Safety and Efficacy of SARS-CoV-2 Vaccination in Patients With Chronic Liver Disease

Abstract Patients with chronic liver diseases (CLDs) have high hospitalization and mortality rates when combined with severe coronavirus disease 2019 (COVID-19) because of defects in humoral and cellular immunity, known as immune dysfunction. COVID-19 vaccines effectively reduce the risk of severe i...

Full description

Saved in:
Bibliographic Details
Published inInfectious diseases & immunity (Online) Vol. 3; no. 3; pp. 120 - 126
Main Authors Mao, Yu-Feng, Gao, Lin, Li, Yuan-Yuan, Wang, Fu-Sheng
Format Journal Article
LanguageEnglish
Published Lippincott Williams & Wilkins 01.07.2023
Wolters Kluwer
Subjects
Review
Online AccessGet full text

Cover

More Information
Summary:Abstract Patients with chronic liver diseases (CLDs) have high hospitalization and mortality rates when combined with severe coronavirus disease 2019 (COVID-19) because of defects in humoral and cellular immunity, known as immune dysfunction. COVID-19 vaccines effectively reduce the risk of severe illness and mortality caused by the virus. Several studies have confirmed the safety and efficacy of the COVID-19 vaccine in patients with CLD, and the existing expert consensus recommends that patients with stable CLD be prioritized for the COVID-19 vaccine. In addition, clinical trials are ongoing to determine the optimal strategy for patients with CLD to receive the COVID-19 vaccine. In this study, we review the progress of research on the safety and efficacy of COVID-19 vaccination in patients with CLD, aiming to provide better recommendations for the vaccination in this population.
ISSN:2096-9511
0025-7974
2693-8839
1536-5964
DOI:10.1097/ID9.0000000000000094